title: A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.
abstract: OBJECTIVE
  The objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia.
  
  
  METHODS
  In this phase II, randomized, double-blind, placebo-controlled study, hospitalized adult patients diagnosed with schizophrenia and experiencing an acute exacerbation of psychotic symptoms were randomly assigned to 6 weeks of fixed-dose lurasidone 20 mg/day (n = 71), lurasidone 40 mg/day (n = 67), lurasidone 80 mg/day (n = 71), haloperidol 10 mg/day (n = 72, included to test for assay sensitivity), or placebo (n = 72). Efficacy was assessed using the brief psychiatric rating scale, positive and negative syndrome scale, and clinical global impression-severity. Safety assessments included incidence of adverse events and clinical laboratory measures.
  
  
  RESULTS
  Numerical improvement was observed from baseline to week 6 (last observation carried forward) on all efficacy measures in all treatment groups; however, no statistically significant differences were noted between any lurasidone group and placebo, or between haloperidol and placebo. The most common adverse events in lurasidone-treated patients, with an incidence of at least 10% (dose groups combined) and greater than placebo, were sedation (15.3%), dyspepsia (13.4%), nausea (13.4%), akathisia (12.4%), and vomiting (10.5%); for haloperidol, the most common adverse events (incidence ⩾ 10% and greater than placebo) were extrapyramidal disorder (20.8%), sedation (19.4%), akathisia (19.4%), dystonia (15.3%), insomnia (13.9%), and somnolence (12.5%). Lurasidone was associated with minimal changes in weight, metabolic parameters, and prolactin levels.
  
  
  CONCLUSIONS
  None of the lurasidone groups separated from placebo in this clinical study of patients with acute schizophrenia. In addition, haloperidol, which was included for assay sensitivity, did not separate from placebo, resulting in a failed study. Possible reasons for the lack of assay sensitivity in this study include the use of multiple active treatment arms and the relatively large placebo response. Consistent with other studies, lurasidone was generally safe and well tolerated, with minimal effects on weight or metabolic parameters.
authors.affiliation: Department of Psychiatry and Human Behavior, University of California-Irvine, 5251 California Avenue, Ste 240, Irvine, CA 92617, USA.
authors.forename: Steven G
authors.initials: SG
authors.lastname: Potkin
authors.affiliation: Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd, Tokyo, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Global Development Administration, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.
authors.forename: John
authors.initials: J
authors.lastname: Guarino
keywords: antipsychotic agents; clinical trial; drug therapy; lurasidone; medication effects; schizophrenia
references.citation: Mol Psychiatry. 2009 Apr;14(4):429-47
references.pmid: 18180760
references.citation: Int Clin Psychopharmacol. 2012 May;27(3):165-76
references.pmid: 22395527
references.citation: J Psychiatr Res. 2013 May;47(5):670-7
references.pmid: 23421963
references.citation: Schizophr Res. 2013 Apr;145(1-3):101-9
references.pmid: 23415311
references.citation: Schizophr Res. 2013 Jun;147(1):95-102
references.pmid: 23583011
references.citation: J Clin Psychiatry. 2013 May;74(5):507-15
references.pmid: 23541189
references.citation: Br J Psychiatry. 1989 May;154:672-6
references.pmid: 2574607
references.citation: Cochrane Database Syst Rev. 2013 Nov 15;(11):CD003082
references.pmid: 24242360
references.citation: J Clin Psychiatry. 2002;63 Suppl 4:56-62
references.pmid: 11913677
references.citation: CNS Spectr. 2014 Aug;19(4):330-9
references.pmid: 24330868
references.citation: Psychopharmacol Bull. 2010;43(4):37-69
references.pmid: 21240151
references.citation: J Pharmacol Exp Ther. 2010 Jul;334(1):171-81
references.pmid: 20404009
references.citation: J Clin Psychopharmacol. 2004 Apr;24(2):192-208
references.pmid: 15206667
references.citation: Br J Psychiatry. 1979 Apr;134:382-9
references.pmid: 444788
references.citation: Eur Psychiatry. 2001 Nov;16(7):418-23
references.pmid: 11728855
references.citation: Psychopharmacol Bull. 2010;43(1):53-72
references.pmid: 20581800
references.citation: Br J Psychiatry. 2006 Nov;189:433-40
references.pmid: 17077434
references.citation: Eur Neuropsychopharmacol. 2014 Jul;24(7):1024-36
references.pmid: 24735806
references.citation: Psychopharmacology (Berl). 2013 Feb;225(3):519-30
references.pmid: 22903391
references.citation: J Clin Psychopharmacol. 2011 Jun;31(3):349-55
references.pmid: 21508856
references.citation: Neuropsychopharmacology. 1996 Feb;14 (2):111-23
references.pmid: 8822534
references.citation: Am J Psychiatry. 2011 Sep;168(9):957-67
references.pmid: 21676992
references.citation: J Clin Psychiatry. 2009 Jun;70(6):829-36
references.pmid: 19497249
references.citation: Acta Psychiatr Scand Suppl. 1970;212:11-9
references.pmid: 4917967
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518